Avalo Therapeutics (AVTX) Other Working Capital Changes (2014 - 2026)

Avalo Therapeutics (AVTX) has 3 years of Other Working Capital Changes data on file, last reported at -$88000.0 in Q4 2023.

• Quarterly Other Working Capital Changes rose 75.14% year-over-year to -$88000.0 in Q4 2023, while the trailing twelve-month figure through Mar 2024 was -$110000.0 (down 200.0% YoY) and the FY2023 annual result came in at -$88000.0, down 200.0% from the prior year.
• Other Working Capital Changes slipped to -$88000.0 in Q4 2023, from $88000.0 in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $4.8 million in Q4 2025 to a low of -$2.5 million in Q1 2025.
• A 5-year average of $217764.7 and a median of $53000.0 in 2024 frame the typical range for Other Working Capital Changes.
• The widest YoY moves for Other Working Capital Changes: up 75.14% in 2023, down 80.09% in 2023.
• Tracing AVTX's Other Working Capital Changes over 3 years: stood at $21412.0 in 2019, then tumbled by 1753.28% to -$354000.0 in 2022, then surged by 75.14% to -$88000.0 in 2023.
• The last three Other Working Capital Changes figures came in at -$88000.0 (Q4 2023), $88000.0 (Q3 2023), and -$110000.0 (Q2 2023), per Business Quant data.